Market Access News | pharmaphorum

News

Novartis and Lilly CEOs back Trump plans to cut drug prices

CEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health system, who have inflated the costs of their medicines.

News

Vertex calls for changes to NICE as CF drug profits soar

Vertex has revealed financial figures that are likely to go down well with investors, but not patients in the UK who are eligible to receive the revolutionary drugs like Orkambi yet are bei

News

FDA accepts Merck & Co's two new antibacterial drug applicat...

The FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Priority Review.

News

Campaigners urge NHS to ignore patents on Vertex's CF drug

The fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called on the government to implement a little-known law allowing to set a

News

Roche seeks Kadcyla boost to fend off Herceptin biosimilars

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla.

News